logo
Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137
rus
русский
eng
english

Site search



Correspondence address
310 Mira Street, Stavropol, Russia, 355017

Tel
+7 8652 352524; +7 8652 353229.

Fax
+7 8652 352524.

E-mail
medvestnik@stgmu.ru

Prognostic markers of recurrence of prostate cancer after radical prostatectomy

[Oncology]
Michail Kogan; Elena Chernogubova; Mikael Chibichyan;

The study identified markers for the prediction of aggressive forms of prostate cancer. The study included 59 patients with prostate cancer who underwent radical prostatectomy, followed by PSA monitoring after 1, 6, 12 and 18 months after surgery. For identification of prostate cancer progression associated index the activity of angiotensinconverting
enzyme (ACE) was determined in the serum. The recurrence of prostate cancer was associated with an increase in ACE activity. At the same time, ACE activity was beginning to rise before the development of biochemical recurrence. Joint determination of PSA and the activity of ACE after 1 month after surgery made it possible to identify a group of patients at high risk for biochemical recurrence with a sensitivity and specificity – 72.7 % (p<0.001) and 91.2 % (p<0.001), respectively. Thus, ACE is a promising prognostic marker of clinically aggressive forms of prostate cancer. Renin-angiotensin system of the organism in prostate cancer can be treated as a new therapeutic «target» for targeted therapy.

Download

References:
1. Arhipova O. E., Chernogubova E. A., Lihtanskaja N. V., Kulygin V. V., Sheverdjaev I. V., Kurolap S. A., Eprincev S. A., Tarasov V. A., D. G. Matishov (red.) Prostranstvenno-vremennoj analiz vstrechaemosti onkologicheskih zabolevanij kak indikatora medikojekologicheskoj bezopasnosti. Rostov-on-Don: Southern Scientific Centre of the Russian Academy of Sciences Publishers; 2014. 224 p.
2. Veliev E. I. Optimizacija hirurgicheskogo lechenija bol’nyh lokalizovannym rakompredstatel’noj zhelezy. Saint Petersburg; 2003. 40 p.
3. Zlokachestvennye novoobrazovaniya v Rossii v 2014 godu (zabolevaemost’ i smertnost’). Pod red. A. D. Karpina, V. V. Starinskogo, G. V. Petrovoy. Moscow Research Oncology Institute of P. A. Herzen of the Russian Ministry of Health; 2016. 250 p.
4. Ognerubova I. N. Onkourologija. – Oncourology. 2013;1:50-54.
5. Golikov P. P. Klinicheskaja Laboratornaja Diagnostika. – Clinical Laboratory Diagnostics. 1998;1:11-13.
6. GOST R 52379–2005 Nacional’nyj standart RF «Nadlezhashhaja klinicheskaja praktika» (Good Clinical Practice; GCP), (utverzhden prikazom Federal’nogo agentstva po tehnicheskomu regulirovaniju i metrologii ot 27 sentjabrja 2005 g. N 232-st).
7. Kogan M. I., Chernogubova E. A., Chibichjan M. B., Macionis A. Je., Povilajtite P. Je., Matishov D. G. Urologija. – Urology. 2015;3:50-54.
8. Kugaevskaja E. V., Timoshenko O. S., Solov’eva N. I. Biomedicinskaja himija. – Biomedical Chemistry. 2015;61(3):301-311.
9. Shishkin S. S., Kovalev L. I., Kovaleva M. A., Krahmaleva I. N., Eremina L. S., Makarov A. A., Lisickaja K. V., Loran O. B., Veliev E. I., Ohric V. E. Problemy rannej diagnostiki raka prostaty i vozmozhnosti primenenija novyh potencial’nyh biomarkerov. (Informacionnometodicheskoe pis’mo) – M.: OOO «Original company»; 2009. 45 p.
10. Bauvois B. Oncogene. 2004;23(2):317-329. doi: 10.1038/sj.onc.1207124
11. Boorjian S. A., Eastham J. A., Graefen M., Guillonneau B., Karnes R. J., Moul J. W., Schaeffer E. M., Stief C., Zorn K. C. Eur. Urol. 2012;64:664-675. doi: 10.1016/j. eururo.2011.11.053
12. Carbajo-Lozoya J., Lutz S., Feng Y., Kroll J., Hammes H.P., Wieland T. Cell Signal. 2012;24(6):1261-1269. doi: 10.1016/j.cellsig.2012.02.005
13. George A. J., Thomas W. G., Hannan R. D. Nat. Rev. Cancer. 2010;10:745-759. doi: 10.1038/nrc2945
14. Hunyady L., Catt K. J. Molecular Endocrinology. 2006;20:953-970. doi: 10.1210/me.2004-0536
15. Imai N., Hashimoto T., Kihara M., Yoshida S., Kawana I., Yazawa T., Kitamura H., Umemura S. Lab. Invest. 2007;87:189-198. doi: 10.1038/labinvest.3700504
16. Nielsen M., Makarov D., Humphreys E., Mangold L., Partin A. W., Walsh P. C. Urol. 2008;72:389-395. doi: 10.1016/j.urology.2007.10.053
17. Rodrigues-Ferreira S., Abdelkarim M., Dillenburg-Pilla P., Luissint A-C., di-Tommaso A., Deshayes F., Pontes C. L. S., Molina A., Cagnard N., Letourneur F. A-C., Morel M., Reis R. I., Casarini D. E., Nahmias C. PLoS ONE. 2012;7(4):1-8. doi: 10.1371/journal.pone.0035667
18. Siegel R., Miller K. D., Jemal A. Cancer J. Clin. 2015;65(1):5-29. doi: 10.3322/caac.21254
19. Wegman-Ostrosky T., Soto-Reyes E., Vidal-Millán S., Sánchez-Corona J. J. Renin Angiotensin Aldosterone Syst. 2015;16(2):227-233. doi: 10.1177/ 1470320313496858

Keywords: prostate cancer, angiotensin converting enzyme, biochemical recurrence, prognostic markers, radical prostatectomy


Founders:
Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy